LONDON, October 4, 2013 /PRNewswire/ --
On Thursday, October 3, 2013, all three benchmark indexes of the US equity market closed lower, with the Dow Jones Industrial Average, the S&P 500, and the NASDAQ Composite falling by 0.90%, 0.90%, and 1.07%, respectively. Shares in the medical appliances and equipment industry ended mostly on a lower note, tracking losses in the broader market. The major movers included Hologic Inc. (NASDAQ: HOLX), St. Jude Medical Inc. (NYSE: STJ), ResMed Inc. (NYSE: RMD), and Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB). All these companies are tracked by AAAResearchReports.com. Download free technical analysis and charting reports on HOLX, STJ, RMD, and NAVB now at:
Hologic Inc.'s stock fell by 0.67% on Thursday, tracking losses in the broader market. The company's shares oscillated between $20.68 and $21.06 before ending the day at $20.86. A total of 3.36 million shares were traded, which is below the daily average volume of 3.55 million. The company's shares have gained 9.62% in the previous three months and 1.07% in the last three trading sessions, compared to a gain of 3.92% and loss of 0.17% in the S&P 500 during the respective periods. Moreover, Hologic Inc.'s stock is trading below its 50-day and 200-day moving averages of $21.35 and $21.17, respectively. Download free research on HOLX today by registering at:
On Thursday, St. Jude Medical Inc.'s stock hit a 52-week high of $55.00 before declining and closing the day at $54.79, which is 0.07% lower than the previous day's closing price of $54.83. The company's shares fluctuated between $53.94 and $55.00 during the trading session. A total of 2.31 million shares were traded, which is above the daily average volume of 1.53 million. However, despite Thursday's decline, the company's shares have gained 8.97% in the last one month and 20.15% in the previous three months, outperforming the S&P 500 which has gained 2.37% and 3.92% during the respective periods. Furthermore, St. Jude Medical Inc.'s stock is trading above its 50-day and 200-day moving averages of $52.46 and $47.13, respectively. Sign up and have access to our free report on STJ at:
ResMed Inc.'s shares edged higher on Thursday, reversing most of the losses from the previous trading session. The company's shares closed at $53.37, up 0.34%, after oscillating between $53.19 and $53.90. A total of 1.23 million shares were traded, which is above the daily average volume of 0.99 million. The company's shares have surged 19.69% in the last three months and 12.38% in the previous one month, outperforming the S&P 500 which has gained 3.92% and 2.37% during the respective periods. Further, ResMed Inc.'s stock is trading near its 52-week high of $54.39 as well as above its 50-day and 200-day moving averages of $50.80 and $47.84, respectively. Sign up and read the complimentary report on RMD at:
Shares in Navidea Biopharmaceuticals Inc. fell sharply on Thursday finishing the day 1.56% lower than the previous day's closing price of $2.56. The company's shares closed at $2.52 after oscillating between $2.49 and $2.58 during the trading session. A total of 1.04 million shares were traded, which is above the daily average volume of 0.63 million. Navidea Biopharmaceuticals Inc.'s shares have lost 4.91% in the previous three trading sessions, underperforming the S&P 500 which has lost 0.17% during the same period. Additionally, the company's stock is trading below its 50-day and 200-day moving averages of $2.86 and $2.70, respectively. The free report on NAVB can be downloaded by signing up now at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE AAA Research Reports